$1.29 Billion is the total value of Avoro Capital Advisors LLC's 45 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 40.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $206,058,000 | +122.5% | 14,739,461 | +40.5% | 15.98% | +36.7% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $97,072,000 | +62.5% | 6,437,122 | +8.5% | 7.53% | -0.2% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $65,842,000 | +88.4% | 5,353,029 | +28.2% | 5.11% | +15.7% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $64,742,000 | +391.4% | 785,700 | +458.4% | 5.02% | +202.0% |
| MDCO | Buy | MEDICINES CO | $63,723,000 | +51.2% | 1,720,393 | +55.1% | 4.94% | -7.1% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $59,309,000 | +115.6% | 1,636,124 | +65.1% | 4.60% | +32.5% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $55,653,000 | +22.4% | 597,972 | +19.4% | 4.32% | -24.8% |
| PCRX | Buy | PACIRA PHARMACEUTICALS INC | $49,245,000 | +121.6% | 1,311,460 | +181.5% | 3.82% | +36.1% |
| HZNP | New | HORIZON PHARMA PLC | $44,584,000 | – | 3,516,100 | +100.0% | 3.46% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $43,414,000 | +422.7% | 3,710,601 | +63.1% | 3.37% | +221.0% |
| AVXS | New | AVEXIS INC | $42,242,000 | – | 436,702 | +100.0% | 3.28% | – |
| DERM | Buy | DERMIRA INC | $41,040,000 | +6.3% | 1,520,000 | +14.7% | 3.18% | -34.7% |
| ZGNX | New | ZOGENIX INC | $35,974,000 | – | 1,026,368 | +100.0% | 2.79% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $34,910,000 | +48.4% | 1,124,300 | +30.7% | 2.71% | -8.8% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $32,560,000 | +6.7% | 4,201,343 | +1.2% | 2.52% | -34.5% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $31,678,000 | +152.7% | 907,162 | +49.4% | 2.46% | +55.2% |
| TLGT | Buy | TELIGENT INC | $30,720,000 | -18.7% | 4,578,230 | +10.8% | 2.38% | -50.1% |
| New | INTEC PHARMA LTD | $19,652,000 | – | 2,195,705 | +100.0% | 1.52% | – | |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $17,690,000 | +20.3% | 988,270 | +9.5% | 1.37% | -26.1% |
| MYOK | New | MYOKARDIA INC | $17,063,000 | – | 398,207 | +100.0% | 1.32% | – |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $11,682,000 | +11.2% | 4,635,745 | +21.8% | 0.91% | -31.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $9,713,000 | +112.4% | 429,600 | +99.3% | 0.75% | +30.5% |
| ALIM | Buy | ALIMERA SCIENCES INC | $8,426,000 | +2.9% | 6,241,581 | +5.9% | 0.65% | -36.8% |
| FOLD | Buy | AMICUS THERAPEUTICS INCcall | $8,400,000 | +1478.9% | 3,000,000 | +1100.0% | 0.65% | +873.1% |
| VCYT | Buy | VERACYTE INC | $8,217,000 | +8.7% | 936,909 | +3.2% | 0.64% | -33.3% |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $8,216,000 | – | 193,600 | +100.0% | 0.64% | – |
| IMMU | New | IMMUNOMEDICS INCcall | $6,300,000 | – | 875,000 | +100.0% | 0.49% | – |
| VIVE | Buy | VIVEVE MEDICAL INC | $5,414,000 | -5.2% | 1,033,276 | +29.9% | 0.42% | -41.7% |
| OVAS | Buy | OVASCIENCE INC | $1,593,000 | +225.8% | 1,121,952 | +258.1% | 0.12% | +100.0% |
| FENC | New | FENNEC PHARMACEUTICALS INC | $731,000 | – | 66,666 | +100.0% | 0.06% | – |
| SPY | New | SPDR S&P 500 ETFput | $469,000 | – | 250,000 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.